Loss of progesterone receptor is associated with distinct tyrosine kinase profiles in breast cancer by Tahiri, Andliena et al.
Vol.:(0123456789) 
Breast Cancer Research and Treatment (2020) 183:585–598 
https://doi.org/10.1007/s10549-020-05763-7
PRECLINICAL STUDY
Loss of progesterone receptor is associated with distinct tyrosine 
kinase profiles in breast cancer
Andliena Tahiri1,3 · Xavier Tekpli2,3 · Somisetty V. Satheesh4 · Rik DeWijn5 · Torben Lüders1,3 · Ida R. Bukholm6 · 
Antoni Hurtado7,8 · Jürgen Geisler3,9 · Vessela N. Kristensen2,3 
Received: 3 April 2020 / Accepted: 20 June 2020 / Published online: 24 July 2020 
© The Author(s) 2020
Abstract
Purpose The aim of this study was to assess protein tyrosine kinase profiles in primary breast cancer samples in correlation 
with the distinct hormone and growth receptor profiles ER, PR, and HER2.
Experimental design Pamchip® microarrays were used to measure the phosphorylation of 144 tyrosine kinase substrates 
in 29 ER+ breast cancer samples and cell lines MCF7, BT474 and ZR75-1. mRNA expression data from the METABRIC 
cohort and publicly available PR chip-sequencing data were used for validation purposes, together with RT-PCR.
Results In ER+ breast tumors and cell lines, we observed that the loss of PR expression correlated to higher kinase activ-
ity in samples and cell lines that were HER2−. A number of kinases, representing mostly proteins within the PI3K/AKT 
pathway, were identified as responsible for the differential phosphorylation between PR− and PR+ in ER+/HER2− tumors. 
We used the METABRIC cohort to analyze mRNA expression from 977 ER+/HER2− breast cancers. Twenty four kinase-
encoding genes were identified as differentially expressed between PR+ and PR−, dividing ER+/HER2− samples in two 
distinct clusters with significant differences in survival (p < 0.05). Four kinase genes, LCK, FRK, FGFR4, and MST1R, were 
identified as potential direct targets of PR.
Conclusions Our results suggest that the PR status has a profound effect on tyrosine kinases, especially for FGFR4 and 
LCK genes, in ER+/HER2− breast cancer patients. The influence of these genes on the PI3K/AKT signaling pathway may 
potentially lead to novel drug targets for ER+/PR− breast cancer patients.
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Introduction
Breast cancer is a complex disease, and depending on the 
molecular profiles of the tumor, it can be classified into 
several distinct intrinsic subtypes with different prognostic 
Antoni Hurtado and Jürgen Geisler have contributed equally to 
this work.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s1054 9-020-05763 -7) contains 
supplementary material, which is available to authorized users.
 * Vessela N. Kristensen 
 vessela.kristensen@medisin.uio.no
1 Department of Clinical Molecular Biology (EpiGen), 
Akershus University Hospital, Lørenskog, Norway
2 Department of Medical Genetics, Oslo University Hospital, 
Oslo, Norway
3 Institute of Clinical Medicine, University of Oslo, Oslo, 
Norway
4 Hamilton Nordics, Slattum, Norway
5 PamGene International B.V., ‘s-Hertogenbosch, 
The Netherlands
6 Helgelandssykehuset HF and Norwegian University of Life 
Sciences (NMBU), Ås, Norway
7 Department of Biomedical Sciences, Faculty of Medicine, 
University of Barcelona, Casanova, Barcelona, Spain
8 August Pi I Sunyer Research Center (IDIBAPS), Barcelona, 
Spain
9 Department of Oncology, Akershus University Hospital, 
Lørenskog, Norway
586 Breast Cancer Research and Treatment (2020) 183:585–598
1 3
outcome [1, 2]. The overall tumor biology of breast cancer 
subtypes is highly dependent on the expression of estrogen 
receptor (ER), progesterone receptor (PR) and the human 
epidermal growth factor receptor 2 (HER2). One of the most 
fundamental clinical distinctions between breast cancer sub-
types is whether the tumor responds to growth signaling 
through the hormonal (ER/PR) or HER2 receptors, as these 
tumors can be targeted with modern anti-hormonal or anti-
HER2 therapy, respectively. Positivity for ER, PR and HER2 
has therefore become highly important in the clinical man-
agement of breast cancer, both in the neoadjuvant/adjuvant 
and metastatic setting of the disease. Approximately 70% 
breast cancers are hormone receptor (HR) positive, meaning 
that they either express ER and/or PR to some extent [3]. In 
ER+ breast cancers, PR is often used as a positive prognos-
tic marker of disease outcome [4], but the role of PR signal-
ing in these cancers, still remains unclear. In advanced breast 
cancer, around 65% of all HR-positive breast cancer patients 
respond well to endocrine therapy [5, 6], whereas patients 
that are ER positive and PR negative (ER+/PR−) have sig-
nificantly worse prognosis [7–9]. The PR is an ER-regu-
lated gene, and ER+ tumors are usually also PR+, whereas 
ER- tumors are usually PR−. Therefore, single HR-positive 
(i.e., ER+/PR− or ER−/PR+) tumors represent only a small 
subgroup of breast cancer cases [10]. While the majority of 
tumors are HR positive, nearly 15–20% of all breast cancer 
patients exhibit HER2 overexpression or HER2/neu gene 
amplification. HER2− positive (HER2+) tumors are very 
heterogeneous, and in many cases, the overexpression of 
HER2 is associated with the loss of both ER and PR expres-
sion, but for 10% of breast cancers, both ER and HER2 are 
co-expressed [11]. Women with both HER2- and HR-pos-
itive cancers do have a tendency to exhibit early resistance 
towards endocrine therapy [12]. However, the prognostic 
impact of HER2 in breast cancer and the effectiveness of 
its drug target are well established in breast cancer patients, 
whereas the role of other protein tyrosine kinases (PTKs) 
in the loop of networks in ER+ breast cancer patients is 
rather unknown. PTKs have for a long time been consid-
ered as potent targets for the treatment of cancer as they are 
important mediators of signaling cascades, and may facili-
tate tumor progression. Nearly half of the tyrosine kinase 
complement is deregulated in cancer [13], which has led to 
the recognition of deregulated PTKs as potential biomark-
ers for stratifying patients to personalized treatments [14, 
15]. In this study, we report a comprehensive analysis of 
tyrosine kinase activity in HR-positive breast tumors that are 
either HER2+ or HER2−. To our knowledge, profiling of a 
large number of PTKs in primary breast cancer specimens 
has not previously been performed, and will add valuable 
information regarding the aspect of molecular profiles of 
breast tumors, and will be important in identifying important 
biomarkers for clinical intervention.
Materials and methods
Tissue specimens
All breast cancer tissue specimens were collected at Aker-
shus University Hospital between 2012 and 2014. After 
surgical removal, tumor tissues were flash frozen in liquid 
nitrogen prior to transportation and then stored at − 80 °C. A 
specialized breast cancer pathologist performed histopatho-
logical examination of the tumor tissue. In total, we included 
32 breast cancer samples for a comprehensive PTK profil-
ing. Subjects involved in the study are mostly HR positive 
(ER+ and/or PR+) and either HER2+ or HER2−, based 
on pathological assessment (See supplementary file 1 for 
detailed sample information). Three samples were excluded 
from subsequent analysis due to ER negativity. Each speci-
men was sectioned with a cryotome to get ~ 80 mg of tissue 
that was used for PTK phosphorylation profiling.
Cell lines
Three ER+ breast cancer cell lines were used for PTK pro-
filing: MCF7, ZR75-1 and BT474. The cell lines have pre-
viously been described [16, 17], and western blotting was 
performed to assess ER, PR and HER2 expression (see sup-
plementary file 2). The breast cancer cell lines were obtained 
from American Type Culture Collection (ATCC, Manassas, 
VA). ZR75-1 cells were grown in RPMI 1640 (21875091; 
Invitrogen). MCF7 and BT474 cells were plated in DMEM 
(4.5 g/l glucose; DMEM; 41966-052; Invitrogen), supple-
mented with 10% FBS, 4 mM l-glutamine, 0.01 mg/ml insu-
lin, 1 mM Na-pyruvate. The cells were grown and treated 
in the presence and absence of 10 nM of 17β-estradiol for 
10 min, as previously described [18].
Cell lysis and protein level determination
All breast tumor samples and cell line pellets were lysed 
with the mammalian protein extraction reagent (M-PER) 
buffer (Pierce Biotechnology, Inc., Rockford, IL), supple-
mented with 1:100 Halt Phosphatase and Protease inhibitor 
cocktail (EDTA free) (Pierce Biotechnology, Inc). The pro-
tein concentration of lysates was determined using the BCA 
assay (Pierce Biotechnology, Inc.).
Pamchip protein tyrosine kinase arrays 
and statistical analysis
PTK profiling was performed using the Tyrosine Kinase 
PamChip® Array for Pamstation®12 (PamGene Inter-
national B.V., ‘s-Hertogenbosch, The Netherlands) as 
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previously described [19]. For each experiment, 10 µg of 
protein lysate was added to the reaction mixture. Each run 
was performed with 12 different tumor samples, and the 
run was repeated three times to assess technical variation 
across samples. For the subsequent data analysis, the end-
level kinetic log2 value for each peptide was used. Saturated 
spots were removed from the analysis, as well as peptides 
that had low signals in the majority of the samples. Here, we 
used a cut-off of 25%, meaning that only peptides that were 
detected in at least 25% of the samples were included, leav-
ing us with a total of 104 peptides for subsequent analysis. 
Technical replicates were averaged and log2 transformed, 
and replicates with high variation among replicates were 
excluded from the analysis. For the experiments involving 
cell lines, we compared PTK profiling of lysates of untreated 
cells (E0) against cells treated with 17β estradiol for 10 min 
(E10). PTK profiling with cell lines was performed using 
two technical replicates per condition, and the run was per-
formed in a single experiment.
Upstream kinase analysis
BioNavigator software v.6 (PamGene) was used to perform 
upstream PTK analysis by comparing differences between 
ER+/HER2−/PR+ and ER+/HER2−/PR− samples, and 
linking them to the putative upstream kinases responsi-
ble for the difference in phosphorylation between the two 
groups. The method uses in silico predictions to identify the 
upstream kinases through Kinexus Kinase Predictor (www.
phosp honet .ca), as previously described [20, 21]. The pro-
gram calculates a significance score or specificity score of a 
kinase Q = − 10log [max(m/M, 1/M)], where m is the num-
ber of times out of M permutations that | τp | >| τ |, where τp 
is the value of the difference statistic obtained after permuta-
tion of the sample or peptide labels, respectively. Kinases are 
then ranked based on the sum of both scores [21].
RT‑PCR
Total RNA was extracted from all specimens using TRIzol 
(Invitrogen, Carlsbad, CA) in combination with RNeasy 
Mini Kit (Qiagen, Valencia, CA). The method combines phe-
nol/guanidine-based lysis and silica membrane column puri-
fication of total RNA. RT-PCR was performed in triplicates 
for 24 breast cancer tissue samples, and for cell lines, using 
the previously described validation strategies [22]. Primers 
used for this project were, fyn-related Src family tyrosine 
kinase (FRK), fibroblast growth factor receptor 4 (FGFR4), 
Lymphocyte Cell-Specific Protein Tyrosine Kinase (LCK), 
Macrophage Stimulating 1 Receptor (MST1R), ERBB2, 
Estrogen Receptor 1 (ESR1), and the control genes ubiq-
uitin C (UBC) and TATA box Binding Protein (TBP) (see 
supplementary file 3 for primer sequence).
METABRIC cohort
The breast cancer mRNA expression dataset disclosed by the 
Molecular Taxonomy of Breast Cancer International Con-
sortium (METABRIC) study (EGAS00000000083) was used 
[23]. Only ER+ breast cancer samples (n = 1052), divided 
into four different categories, were used for analysis. We 
have analyzed ER+/HER2−/PR+ (n = 680) against ER+/
HER2−/PR- (n = 297) samples, and ER+/HER2+/PR+ sam-
ples (n = 33) against ER+/HER2+/PR− (n = 42) samples. 
There were 977 ER+/HER2− samples. Furthermore, 24,368 
genes were identified to be expressed above background lev-
els and used for further analysis.
Chip‑sequencing data
ChIP-sequencing data from MCF7 cell line were obtained 
from a previously published dataset [24] where MCF7 cells 
were treated with either 100 nM progesterone (PG2) or etha-
nol (vehicle) for three constitutive days.
Data analysis
Signal quantification on phosphorylated peptides and quality 
control was performed in BioNavigator software v.6 (Pam-
Gene International, ‘s-Hertogenbosch, the Netherlands) as 
previously described [21], and the data were exported to 
R. All statistical analyses were consequently performed in 
the R software (r-project.org), unless otherwise specified. 
The pheatmap package was used for heatmaps and cluster-
ing, and differential expression (p < 0.05) was calculated 
in microarray data using R software. Pathway analysis was 
performed using DAVID Bioinformatics resources [25, 26] 
and Gene Set Enrichment Analysis (GSEA) [27, 28]. The 
microarray data are deposited in GEO database (GEO acces-
sion: pending).
Results
Protein tyrosine kinase activity profiling 
in ER‑positive breast cancer samples and cell lines
Microarrays were used to profile the phosphorylation of 
substrate kinases in the primary tumors of ER+ breast can-
cer patients that were either HER2+ or HER2−. Figure 1a 
shows the basal phosphorylation of 104 peptides (kinase 
substrates) in 29 primary breast tumors. Based on the level 
of phosphorylation of the kinase substrates, reflecting the 
kinase activity, we identified three clusters of peptides 
through unsupervised clustering, showing different levels 
of kinase activity. Peptides in cluster 1 exhibited overall very 
high levels of phosphorylation, whereas peptides in clusters 
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2 and 3 displayed moderate and low levels, respectively (see 
supplementary file 4 for information of peptide clusters). 
The unsupervised clustering distributed the patients in two 
main groups; one group with lower peptide phosphorylation 
in each of the clusters identified, and a second group with 
higher phosphorylation (Fig. 1a). Interestingly, the patients 
identified at the cluster with lower phosphorylation, were 
more likely to be PR+ compared to patients identified at 
peptide clusters with higher phosphorylation peptides (9 out 
of 11 (~ 82%) at lower vs. 13 out of 18 (~ 72%) at higher 
phosphorylation, p = 3.39E−06). Next, we sought for differ-
ences in peptide phosphorylation associated with HER2 and 
PR expression. In this dataset, we found no statistically sig-
nificant differences in the level of phosphorylation in overall 
kinase activity between differential HER2 and PR status in 
ER+ tumors, nor within the three clusters of peptides iden-
tified (see supplementary file 5). Although not significant, 
we did observe a trend of increased phosphorylation in PR- 
samples compared to PR+ samples.
To further investigate the kinase activity patterns, we per-
formed in parallel PTK profiling in the well-established ER+ 
cell lines, MCF7, ZR75-1 and BT474. Western blot of HER2, 
ER and PGR was performed, showing that they were rep-
resentative of the human breast tumors with different levels 
of proteins of HER2 and PR (MCF7 as ER+/HER2−/PR+, 
BT474 as ER+/HER2+/PR+ and ZR751 as ER+/HER2+/
PR-, supplementary file 2). Next, PTK profiling was per-
formed on all the cell lines, which were either untreated (E0) 
or exposed to estrogen (17β- estradiol) for 10 min (E10) 
(Fig. 1b). The use of estradiol aimed to test whether estrogen 
signaling might influence the kinase activity. Our findings 
indicated that treating cell lines with estradiol did not have a 
significant impact on the overall activity of PTKs in HER2+ 
cell lines (ZR75-1 and BT474). However, in the HER2− cell 
line (MCF7), we found a significant increase of peptide phos-
phorylation in response to estrogen treatment (supplementary 
file 6). Furthermore, the analysis revealed that the ZR75-1 cell 
line, which is a PR- cell line, exhibited increased kinase activ-
ity in contrast to the two other cell lines, MCF7 and BT474. 
The kinase substrates that exhibited higher phosphorylation 
in ZR75-1 were overlapping with those exhibiting high phos-
phorylation in cluster 1 and some in cluster 2 from the patient 
sample data from Fig. 1a. These results motivated us to inves-
tigate further the role of PR in tumor tissue.
PR expression with great influence 
on phosphorylation in ER+/HER2− tumors
To further investigate the correlation between PR and PTKs, 
we analyzed the average kinase activity in different cell lines 
Fig. 1  Unsupervised analysis showing phosphorylation profiles of 
tyrosine kinase substrates in a 29 primary ER-positive breast cancer 
tumors and b ER-positive breast cancer cell lines, MCF7, BT474, and 
ZR75-1, before (E0) and after (E10) treatment with estradiol (E). The 
heatmap visualizes log2-transformed signal intensities retrieved from 
tyrosine kinase substrate arrays incubated with sample lysates, in 
which the samples (horizontal axis) and 104 peptides (vertical axis) 
are sorted according to principles of hierarchical clustering. Red cor-
responds to higher and blue to lower kinase substrate phosphoryla-
tion levels. ER− estrogen receptor, PR− progesterone receptor, and 
HER2− human epidermal growth factor receptor 2
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(Fig. 2a, b and c) and patient tumor subgroups based on 
the PR and HER2 status in each of the three peptide clus-
ters (Fig. 2d, e and f). Especially in cluster 1 and cluster 2 
peptides, the overall PTK activity levels were significantly 
increased in the PR- cell line, ZR75-1. In breast tumors, 
we clearly identified that the subgroup ER+/HER2−/PR- 
showed overall higher kinase activity compared to the 
other PR+ subgroups in all three peptide clusters identified 
through unsupervised clustering in Fig. 1a. Through statisti-
cal testing, a total of 30 kinase substrates, representing 26 
different PTKs, were identified as significantly differently 
phosphorylated in ER+/HER2− tumors according to PR 
status (Table 1). We did not find any differences in phos-
phorylated peptides when the same analysis was performed 
with ER+/HER2+ breast cancer samples (data not shown).
In our analysis, PR- tumors showed higher kinase 
activity of these 30 kinase substrates compared to PR+ 
tumors within the ER+/HER2− subgroup, as reflected by 
higher mean phosphorylation values. Several membrane 
residing PTK receptors showed higher phosphorylation 
in ER+/HER2−/PR- tumors, including HER2, insulin 
receptor (INSR), vascular endothelial growth factor recep-
tor (VEGFR), fibroblast growth factor receptor (FGFR), 
erythropoietin receptor (EPOR) and Erythropoietin-Pro-
ducing Hepatoma Receptor (EPHA). Through pathway 
analysis [25, 26], we identified several of the PTKs to be 
part of the phosphoinositide-3-kinase/Akt (PI3K) signal-
ing pathway (p value 4.10E−08, benjamini 4.47E−06), 
Ras signaling pathway (p value 1.47E−07, benjamini 
5.33E−06) VEGF pathway (p value 9.61E−05, benjamini 
7.48E−04) and ErbB pathway (p value 5.03E−03, ben-
jamini 2.58E−02). In order to identify the kinases that 
might be responsible for the differential phosphorylation 
of kinase substrates in ER+/HER2− tumors with differ-
ential PR status, we performed upstream kinase analysis 
as described above. In total, 75 kinases were identified, 
with the ones on the top of the table being more likely to 
be responsible for the changes in kinase phosphorylation 
Fig. 2  Boxplots of mean phosphorylation of peptides in cluster 1, 
2, and 3 in three different ER+ cell lines and a–c and different sub-
groups of ER+ breast cancer samples (d–f). The three peptide clus-
ters are the same as the peptide clusters obtained from unsupervised 
clustering in Fig.  1a. Statistical significance between subgroups/cell 
lines in each cluster is indicated by p values < 0.05 in tables. ER− 
estrogen receptor, PR− progesterone receptor, HER2− human epider-
mal growth factor receptor 2
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levels between PR+ and PR− in ER+/HER2− tumors 
(Fig. 3). In agreement with the previous pathway analysis, 
RAS signaling (p value 6.9E−8, benjamini 2.2E−6), PI3K 
signaling (p value 5.3E−06, benjamini 1.0E−04) and ErbB 
signaling pathways (p value 1.6E−5, benjamini 2.5E−4) 
were identified as the top pathways to be involved in the 
difference of upstream kinases between PR− and PR+ in 
ER+/HER2− tumors. Altogether, our findings so far sug-
gest that the loss of PR leads to increased kinase activation 
in ER+/HER2−/PR− tumors, involving the PI3K pathway.
mRNA expression differs in ER+/HER2− breast 
tumors based on PR status
Our data have so far suggested that the loss of PR expres-
sion might ameliorate the activation of kinases in ER+/
HER2− tumors and cell lines. In order to explore fur-
ther the relation of PR expression in HER2− tumors, we 
exploited the mRNA expression dataset from the META-
BRIC cohort [23], using data from only ER+ tumors 
(n = 1052). Our analysis revealed a set of 648 genes that 
were identified as significantly differentially expressed 
Table 1  Kinase substrates (p < 0.05) showing difference in activity in PR+ and PR− in ER+/HER2− breast tumors
LFC log fold change, P p.value, PR progesterone receptor
* Corrected p value
Substrate ID Gene symbol Gene name p (raw) q* PR − mean PR+ mean LFC
41_654_666 EPB41 Erythrocyte membrane protein band 4.1 2.7E−03 1.7E−03 9.68 8.82 − 0.85
B3AT_39_51 SLC4A1 Solute carrier family 4, anion exchanger, member 1 4.2E−03 3.3E−03 5.34 2.58 − 2.76
CD3Z_146_158 CD247 CD247 molecule 6.9E−03 5.0E−03 7.02 5.19 − 1.83
CDK2_8_20 CDK2 Cyclin-dependent kinase 2 7.2E−03 6.7E−03 10.99 9.96 − 1.02
CRK_214_226 CRK v-crk sarcoma virus CT10 Oncogene homolog 8.8E−03 8.3E−03 6.02 3.24 − 2.78
EGFR_1165_1177 EGFR Epidermal growth factor receptor 1.5E−02 1.0E−02 5.90 4.56 − 1.34
EPHA1_774_786 EPHA1 EPH receptor A1 1.6E−02 1.2E−02 9.87 8.82 − 1.06
EPHA2_765_777 EPHA2 EPH receptor A2 1.9E−02 1.3E−02 10.25 9.12 − 1.13
EPHA7_607_619 EPHA7 EPH receptor A7 2.1E−02 1.5E−02 9.15 8.11 − 1.04
EPHB1_771_783 EPHB1 EPH receptor B1 2.2E−02 1.7E−02 9.13 7.97 − 1.16
EPHB1_921_933 EPHB1 EPH receptor B1 2.2E−02 1.8E−02 6.53 3.80 − 2.73
EPOR_361_373 EPOR Erythropoietin receptor 2.2E−02 2.0E−02 9.21 8.19 − 1.02
EPOR_419_431 EPOR Erythropoietin receptor 2.6E−02 2.2E−02 8.49 6.87 − 1.62
ERBB2_1241_1253 ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene 
homolog 2
2.7E−02 2.3E−02 6.76 5.22 − 1.54
ERBB2_870_882 ERBB2 v-erb-b2 erythroblastic leukemia viral oncogene 
homolog 2
3.1E−02 2.5E−02 6.83 5.12 − 1.70
FES_706_718 FES Feline sarcoma oncogene 3.1E−02 2.7E−02 10.26 9.18 -1.08
FGFR3_753_765 FGFR3 Fibroblast growth factor receptor 3 3.3E−02 2.8E−02 7.73 6.23 − 1.50
INSR_992_1004 INSR Insulin receptor 3.3E−02 3.0E−02 5.29 3.08 − 2.22
JAK2_563_577 JAK2 Janus kinase 2 3.5E−02 3.2E−02 7.79 6.68 − 1.12
LCK_387_399 LCK Lymphocyte-specific protein tyrosine kinase 3.7E−02 3.3E−02 8.68 7.61 − 1.07
MK14_173_185 MAPK14 Mitogen-activated protein kinase 14 3.8E−02 3.5E−02 5.11 3.17 − 1.94
ODBA_340_352 BCKDHA Branched chain keto acid dehydrogenase E1. alpha 
polypeptide
4.0E−02 3.7E−02 5.78 2.93 − 2.85
P85A_600_612 PIK3R1 Phosphoinositide-3-kinase, regulatory subunit 1 
(alpha)
4.3E−02 3.8E−02 10.50 9.17 − 1.32
PAXI_24_36 PXN Paxillin 4.3E−02 4.0E−02 10.38 9.02 − 1.37
PDPK1_369_381 PDPK1 3-phosphoinositide-dependent protein kinase-1 4.6E−02 4.2E−02 8.52 7.75 − 0.77
RET_1022_1034 RET Ret proto-oncogene 4.7E−02 4.3E−02 9.82 8.84 − 0.98
STAT4_714_726 STAT4 Signal transducer and activator of transcription 4 4.7E−02 4.5E−02 6.05 3.90 − 2.15
VGFR1_1040_1052 FLT1 FMS-related tyrosine kinase-1 4.7E−02 4.7E−02 5.54 3.62 − 1.92
VGFR2_1046_1058 KDR Kinase insert domain receptor 4.8E−02 4.8E−02 5.17 2.71 − 2.46
VGFR2_989_1001 KDR Kinase insert domain receptor 4.8E−02 5.0E−02 9.53 8.48 − 1.05
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(Bonferroni corrected p value < 0.05) between PR+ and 
PR− in HER2− tumors (n = 977) (supplementary file 
7), with most of the genes being involved in pathways 
related to tyrosine kinase activity, and also immunity 
(supplementary file 8). Survival analysis with all 648 
genes revealed that patients that lack PR in ER+ tumors, 
had significantly worse survival than patients that were 
PR+ (see supplementary file 10). Again, no significant 
Fig. 3  Upstream kinases responsible for changes in ER+/HER2− 
tumors with differential PR status. There are 75 putatively affected 
kinases (y axis) in ER+/HER2− tumors that are negatively expressed 
in PR+ (i.e., positive expressed in PR−). Length of the bars indicates 
the value of τ for each of these kinases. (τ > 0 indicates lower activity 
in PR+ samples compared to PR− samples). The color of the bars 
indicates the specificity score. Positive score means higher expressed, 
whereas negative score indicates low expression of the putative 
kinases. The kinases on the top are more likely to be upstream, com-
pared to the kinases at the bottom of the list
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differences in gene expression based on PR status in ER+/
HER2+ breast tumor samples were observed, except the 
expression of the PGR gene itself (see Supplementary 
file 9). These findings are in agreement with our kinase 
activity data. Among the differentially expressed genes 
(n = 648) identified between PR+ vs. PR− in ER+/
HER2− tumors, we identified 24 genes that encode for 
known human PTKs obtained from previous reports [13]. 
Moreover, we performed a heatmap with hierarchical clus-
tering using the 24 kinase-encoding genes (bonferroni cor-
rected p value < 0.05) across ER+/HER2− breast cancer 
samples. The analysis clearly divided the patients in two 
clusters (cluster 1 and cluster 2) (Fig. 4a). The major-
ity of the PR− tumor samples were grouped together in 
cluster 2, whereas the majority of PR+ tumor samples 
were grouped together in cluster 1, with some exceptions. 
Through survival analysis, we observed that patients in 
cluster 2 with ER+/HER2− tumors have significantly 
worse survival compared to patients in cluster 1 (Fig. 4b). 
Furthermore, patients in cluster 2, which predominantly 
include PR- patients, have a significantly worse survival 
than PR- patients in cluster 1 (Fig. 4c). Even more interest-
ing, PR+ patients seem to have a significant worse survival 
in cluster 2 than PR+ patients in cluster 1 (Fig. 4d). Hence, 
the expression of PR seems to play a role in survival when 
considering these two clusters and the expression of the 24 
kinase genes analyzed in the present study.
Fig. 4  a Heatmap with clustering of 24 kinase-encoding genes that 
are differentially expressed in ER+/HER2− tumors with differen-
tial PR status. Red on the heatmap indicates higher expression lev-
els, whereas blue indicates lower mRNA expression levels. Survival 
analysis of breast tumors grouped by gene expression in cluster 1 
(pink) and cluster 2 (blue) are shown as Kaplan–Meier survival plots 
of patients whose tumors were grouped into b ER+/HER2−, c ER+/
HER2−/PR−, and d ER+/HER2−/PR+. ER estrogen receptor, PR 
progesterone receptor, Her2 human epidermal growth factor 2
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PR regulation through protein tyrosine kinases
Next, we found out that four kinases were part of this 24 
gene list that were also identified in the upstream kinase 
analysis previously. These four kinase genes were, fyn-
related Src family tyrosine kinase (FRK), fibroblast growth 
factor receptor 4 (FGFR4), Lymphocyte Cell-Specific Pro-
tein Tyrosine Kinase (LCK), and Macrophage Stimulating 
1 Receptor (MST1R). They were all identified as signifi-
cantly differentially expressed between PR+ and PR− in 
ER+/HER2− tumors (bonferroni p value < 0.05), and all 
involved in the PI3K pathway [29–32]. When analyzing 
the expression of these genes in cluster 1 and cluster 2, 
we identified that FGFR4 and LCK exhibit significantly 
higher expression in cluster 2, whereas FRK and MST1R 
show lower expression in cluster 2 compared to cluster 1 
(supplementary file 11a). Furthermore, FGFR4 and LCK 
showed higher expression in PR− tumors, whereas FRK 
and MST1R show lower expression in PR- tumors. This 
finding was validated with RT-PCR on ER+/HER2− breast 
tumor samples (see supplementary file 11b), except for 
MST1R, which showed no difference between PR+ and 
PR-. Furthermore, in ER+/HER2+ tumors, we did not 
observe the same trend of expression for these four kinases 
(supplementary file 11c). In ER+/HER2+ tumors, it seems 
like at least for LCK and FGFR4, their expression is oppo-
site to what is observed in ER+/HER2− tumors. In ER+/
HER2+ tumors, FGFR4 and LCK have much lower levels 
of FGFR4 and LCK in PR− compared to PR+ tumors. 
To validate our findings experimentally, we determined 
whether PR regulates the gene expression of the four 
identified kinases (FGFR4, LCK, FRK and MST1R) in 
ER+/HER2−/PR+ cells (MCF7). For this purpose, we 
first determined the binding of PR at chromatin regions 
from publicly available ChIP-sequencing data of these 
four kinases investigated [24]. We identified a gain of PR 
binding in cells stimulated with progesterone receptor 
agonists. Furthermore, we analyzed the RNA expression 
of the four kinases in breast cancer cells stimulated with 
progesterone. Briefly, breast cancer cells were plated and 
hormone-deprived for three consecutive days and either 
treated with ethanol (vehicle) or treated with progesterone 
(PG2). Then, the gene expression of FGR4, LCK, FRK 
and MST1R was determined by RT-PCR and compared 
the expression of cells stimulated with progesterone vs 
control cells. Our in  vitro experiments validated that 
the gene expression of LCK and FGFR4 was downregu-
lated by progesterone (Fig. 5a, b), whereas for FRK and 
MST1R, the expression was increased (Fig. 5c, d), which 
is in concordance with the findings in clinical samples. We 
also determined the binding of PR at chromatin regions of 
these four kinases investigated, and we identified a gain of 
PR binding in cells stimulated with progesterone. All these 
findings suggest that PR controls the activity of several 
pivotal kinases in ER+/HER2− patients.
Discussion
Since the clinical success of HER2-targeted therapies, like 
trastuzumab and pertuzumab, there has been an increased 
interest in PTKs as potentially attractive intracellular targets 
for breast cancer treatment. While HER2 has a profound 
impact on breast cancer biology and prognosis, one might 
expect that differences in HER2 status alone would have a 
significant effect on the activity of downstream kinases in 
ER+ breast cancers. However, when analyzing the phos-
phorylation patterns of kinases in ER+ breast cancer sam-
ples and cell lines, we observed no significant differences in 
phosphorylation of kinase substrates that could be correlated 
to HER2 status. However, it is important to mention that 
activation of HER2 may occur through several mechanisms 
in breast cancer [33]. For instance, it has been reported that 
there are rare types of lung cancers that have HER2 kinase 
domain mutations that confer increased kinase activity with-
out overexpression [33]. This could potentially explain why 
we did not observe any differences between HER2+ and 
HER2− in our dataset, at least for the analysis involving 
phosphorylation of kinase substrates.
The role of estrogens and ER in breast cancer is undis-
puted, and drugs inhibiting estrogen synthesis or ER itself 
are effective cancer therapies for HR-positive tumors. How-
ever, the action of PR in breast cancer is still somehow 
underexplored and remains controversial. PR expression is 
induced by the activation of ER, and PR-related signaling 
pathways have important roles in the induction, progression 
and maintenance of neoplastic phenotype in breast cancer 
[34]. Previous research also shows that PR is not merely 
an ERα-induced gene target, but is also an ERα-associated 
protein that modulates its behavior by controlling chroma-
tin binding and transcriptional activity, which has impor-
tant implications for prognosis and therapeutic interventions 
[24]. Although it seems like PR appears to have a profound 
effect on prognosis and aggressiveness of breast cancer, the 
kinases and pathways that come to play is less studied.
In this study, we identified PR as a plausible factor 
responsible for differences in kinase activity within ER+ 
tumors. Higher kinase activity was observed in ER+/
HER2−/PR− tumors compared to tumors that are positive 
for PR expression. Furthermore, using gene expression data 
from the METABRIC cohort [23], we revealed that the loss 
of PR expression had a pronounced effect on survival in ER+ 
patients in general, but the differences were even more sig-
nificant in ER+/HER2− patients, even when including a 24 
kinase-encoding gene signature only. Using the 24-kinase-
encoding-gene signature, we identified two clusters with 
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differences in survival in ER+/HER2− patients. Cluster 
1, which consisted mostly of PR+ patients, exhibited bet-
ter survival than patients in cluster 2, which were mostly 
PR-. Interestingly, the patients within cluster 2 that were 
PR+ had worse survival compared to patients with same 
clinical features in cluster 1, indicating that the expression 
of kinase-encoding genes themselves might indicate worse 
survival altogether. Our data are so far in agreement with 
Fig. 5  PGR binding sites and RNA expression in a LCK, b FGFR4, c FRK, and d MST1R through PR chip sequencing and RT-PCR in 
untreated MCF7 cells (veh) and in cells treated with progesterone (PG2)
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previous studies, which have shown that clinically, the PR 
status exerts a significant impact on the prognosis of ER+ 
breast cancer patients in which patients with PR- tumors 
have a worse outcome than PR+ tumors [35–37]. Prat et al. 
[38] also reported that a cut-off value of > 20% PR tumor cell 
positivity is a significant prognostic factor within luminal-
type breast cancers. Also, the extent of PR expression has 
shown to be a potent prognostic indicator that can aid evalu-
ations of the long-term prognosis of ER+/HER2− breast 
cancers [34]. However, in our study, probably due to the 
small sample set, we could not observe differences in phos-
phorylation in patients with high or low PR tumor cell posi-
tivity, and as for the gene expression data, such differences 
in PR levels were not available. One might speculate that the 
PR+ patients that clustered together with patients that were 
PR- and vice versa could be due to differences of the amount 
of PR− positive tumor cells.
Furthermore, we identified four kinases that were impor-
tant for the differences between PR+ and PR- in ER+/
HER2− tumors, namely FGFR4, LCK, FRK and MST1R. 
These four kinases were identified through upstream analysis 
as potential kinases that might be responsible for changes 
between PR+ and PR− in ER+/HER2− tumors, but they 
were also identified in the METABRIC gene expression 
dataset as significantly differentially expressed between 
these two groups. Interestingly, we could not find any sig-
nificant genes (except PGR) or kinases that were different 
between PR+ and PR− in ER+/HER2+ tumors. One might 
postulate that in ER+/HER2+ tumors, the HER2 pathway 
may be the major driver for tumor growth and hence there 
are less obvious differences observed between PR+ and 
PR- tumors.
FGFR4 and LCK had higher expression in 
HER2−/PR− samples, whereas FRK and MST1R had lower 
expression in HER2−/PR− samples. This was validated in 
breast tumor tissue through RT-PCR, except for MST1R. 
We also identified these kinases to be regulated directly 
by PR itself through PR chip-sequencing data. By adding 
progesterone to MCF7 cells (PR+), we observed that both 
FGFR4 and LCK were reduced in expression, whereas FRK 
and MST1R were increased. This is in concordance with 
our study where we see the complete opposite happening in 
PR- tumors. These findings are in the agreement of the idea 
that PR controls the expression of these kinases in ER+/
HER2− tumors, and the deregulation of their activity might 
confer bad prognosis, and be important in treatment.
While PR+ tumors are associated with better progno-
sis in ER+ breast tumors [4], the loss of PR expression is 
associated with differential breast tumor responses to anti-
ER therapies [7–9]. However, the role of PR activation 
seems to be a bit controversial, because in some studies, 
PR activation seems to promote breast cancer, whereas in 
some studies, progesterone treatment has been shown to be 
anti-proliferative in ER+/PR+ breast cells [39–41]. At the 
same time, previous studies have shown that PR itself can be 
phosphorylated and activated independent of progesterone, 
through different growth factors and pathways, in particu-
lar through MAPK and PI3K/AKT pathway [42]. Experi-
mental data have even implied that growth factor signaling 
mediates PR downregulation through the activation of the 
PI3K–Akt–mammalian target of rapamycin (mTOR) path-
way [7].
Because PR is regulated by estrogen through ER, the ER-
mediated signaling is important in ER+/PR+ tumors. How-
ever, in ER+/PR− tumors, one might hypothesize that they 
rely on other signal transduction pathways to grow because 
ER-mediated signaling is less important in these tumors. 
Therefore, the findings that more kinases were identified 
as differently expressed between PR+ and PR- in ER+/
HER2− cancer is perhaps not completely unexpected. How-
ever, ER+/PR- cell lines are still dependent of ER for tumor 
growth. If ER is depleted in these cell lines, then the tumor 
growth is inhibited. The same happens with hormone resist-
ant cell lines (most of them are PR-). In the case of ER+/
PR− patients, they are less sensitive to hormone therapy but 
still responsive [37]. The findings of the work in this study 
reveal that the loss of PR function leads to an increase of 
activity (and in some cases increase of expression as well) 
of kinases (different to HER2). This effect is not influenced 
by estrogen-ER activation. Hence, we might believe that the 
action is dependent of PR. However, we also know that ER, 
PR, and HER2 are related to each other, and gene signaling 
occur through a loop of network, which make further studies 
a necessity to understand their importance in cancer.
The results obtained in this study clearly demonstrated 
that the Ras/MAPK and PI3K pathways are important, and 
highly active in ER+/HER2− tumors lacking PR. When 
analyzing gene expression data, the PI3K cascade does not 
come up as significant between ER+/HER2− tumors with 
differential PR status, although, tyrosine kinase activity and 
immune pathways seems to be much more prominent. The 
activation of the PI3K pathway and its downstream targets 
is rather complex. Especially breast cancer tumorigenesis 
is believed to depend on the PI3K pathway because the 
majority of breast cancer cases harbor at least one muta-
tion that potentially affects this pathway [34]. Furthermore, 
the PI3K pathway is commonly altered in ER+/HER2− and 
ER+/PR− cancers [37, 43]. The PI3K pathway is activated 
through phosphorylation of several proteins, among them 
also the four tyrosine kinases that we have identified in this 
study.
MST1R encodes for the protein RON, which is a RTK for 
the ligand macrophage-stimulating protein (MSP, MST1). 
Aberrant expression of RON is associated with tumor 
progression in breast cancer through its involvement with 
PI3K, MAPK, JNK, β-catenin, and STAT pathways [44]. 
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Overexpression of RON is associated with cell dissociation, 
motility and matrix invasion, which all are surrogate markers 
of an aggressive cancer phenotype with metastatic potential 
[45]. In our study, the MST1R gene was lower expressed 
in PR− vs PR+ in ER+/HER2− in the METABRIC data-
set, but could not be validated. Since this gene is a marker 
of invasion, and all our samples were primary tumors, this 
could possibly explain the reason why we could not see dif-
ference in expression, and it could most likely be considered 
as a marker of late stage disease.
FRK interacts and phosphorylate the tumor suppressor 
protein PTEN, and through its activation inhibits PI3K/AKT 
signaling pathway [29]. Low levels of FRK show increased 
cell growth, colony formation and tumor growth, whereas 
high levels suppress tumor growth in breast cancer cell lines 
[46]. In our study, FRK is lower expressed in PR− tumors 
compared to PR+ in ER+/HER2− tumors, making it an inter-
esting marker for prognosis and potentially drug interventions.
Phosphorylated FGFR4 recruits and phosphorylates two 
important intracellular targets, phospholipase γ (PLCγ) 
and FGFR substrate 2 (FRS2). The MAPK and PI3K/AKT 
pathway can then be triggered by activated FRS2 through 
recruitment of growth factor receptor bound 2 (GRB2). Pre-
vious research has shown that high levels of FGFR4 mRNA 
could be an independent predictive factor, as high levels of 
FGFR4 show shorter progression-free survival in breast can-
cer patients treated with tamoxifen [30, 47]. The FGFR4 
expression levels also seem to be significantly increased in 
doxorubicin-resistant breast cancer clones [48].
LCK itself is mostly found in T cells, and is involved 
in recruitment and activation of proteins, such as PLC 
and PI3K, that in turns activates the MAPK and PI3K/
AKT pathway [31]. The fact that genes involved in immu-
nity were prominent in PR- compared to PR+ in ER+/
HER2− tumors, makes LCK an important target, as tumor 
infiltrating lymphocytes (TILs) are important components 
of the microenvironment of the cancer. In breast cancer, 
they are associated with clinical outcomes as high TIL 
score is associated with worse prognosis and they pro-
vide prognostic information and can predict the patient’s 
response to neoadjuvant chemotherapy [32]. In our study, 
both FGFR4 and LCK were found to be higher expressed 
in HER2−/PR− tumors vs HER2−/PR+. In HER2+ 
tumors, LCK and FGFR4 seems to be downregulated 
rather than upregulated in PR- tumors, which is the oppo-
site to what we see in HER2− tumors. The fact that this 
overexpression is only observed in ER+/HER2− samples 
and not in ER+/HER2+ samples, seems to agree with 
what we find, that HER2− tumors are indeed much differ-
ent from HER2+ tumors, and that HER2−/PR− are more 
“aggressive” or “oncogenic” in that sense. It could also 
mean that HER2 together with PR regulate their expres-
sion. One could postulate that when HER2 is present, 
HER2 could be more dominant than PR, and thereby the 
oncogenic events might occur through different genes/
pathways. However, when HER2 is missing, other genes 
and pathways are more prominent.
As several studies have pointed out the importance of 
the PI3K pathway during resistance to endocrine therapy 
in breast cancer patients (39), together with the fact that 
ER+/PR+ breast cancer responds better to endocrine ther-
apy compared to ER+/PR- breast cancer [35–37], makes 
it of uttermost importance to study the consequences of 
the loss of PR in ER-positive breast cancers. The kinases 
LCK, FRK, FGFR4 and MST1R, all interacting with pro-
teins within the PI3K pathway, seem to be a good starting 
point according to our findings.
Conclusions
Taken together, our results suggest that loss of PR in ER+ 
breast cancer influences significantly the downstream 
tyrosine kinase signaling, possibly through multiple mech-
anisms and involving several kinases linked to the PI3K 
pathway.
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